Alpha-1 antitrypsin deficiency

Abstract

Alpha-1 antitrypsin deficiency (AATD) is a rare hereditary condition caused by decreased plasma and tissue levels of alpha-1 antitrypsin (AAT) that can lead to serious lung and liver disease in children and adults. AATD patients face challenges such as under diagnosis, clinical variability, and limited treatment options for liver disease. Early detection and biomarkers for predicting outcomes are needed to improve patient outcome. Currently, the only approved pharmacological therapy is augmentation therapy, which can delay the progression of emphysema. However, alternative strategies such as gene therapy, induced pluripotent stem cells, and prevention of AAT polymerization inside hepatocytes are being investigated. This review aims to summarize and update current knowledge on AATD, identify areas of controversy, and formulate questions for further research.

Keywords: Alpha-1 antitrypsin deficiency; COPD; Cirrhosis; Cirrosis; Cáncer de hígado; Déficit de alfa-1 antitripsina; EPOC; Emphysema; Enfermedades raras respiratorias; Enfisema; Liver cancer; Rare respiratory diseases.